Redeye Initiates Coverage of Lipigon
2022-03-15 10:00:00
Redeye initiates coverage of Lipigon, a biotech company developing Lipisense, a new first-in-class ANGPTL-4-targeting candidate, based on modern, state-of-the-art, antisense technology. We believe Lipisense could reduce blood fat in the several million people suffering from SHTG, a condition of extreme triglyceride blood levels that leaves patients at high risk for pancreatitis—implying potential blockbuster status for the candidate.
Read more and download the Research Report.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/